In contrast, the increased CD117 receptor density that we demonstrated on KIT+ NSCLC could conceivably result in cross-phosphorylation and constitutive KIT activity, rendering KIT+ NSCLC tumors dependent on KIT expression and susceptible to its inhibition. The gene discussed is KIT; the disease is non-small cell lung carcinoma.